- Home
- RPRX vs FWONK Comparison
RPRX vs FWONK Comparison
Compare RPRX & FWONK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | FWONK |
|---|---|---|
| Founded | 1996 | 1950 |
| Country | United States | United States |
| Employees | N/A | 1674 |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 21.7B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | RPRX | FWONK |
|---|---|---|
| Price | $52.97 | $89.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $51.40 | ★ $110.88 |
| AVG Volume (30 Days) | ★ 2.8M | 1.8M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $2,378,193,000.00 | N/A |
| Revenue This Year | $38.63 | $24.56 |
| Revenue Next Year | $4.73 | $5.52 |
| P/E Ratio | ★ $79.66 | $107.00 |
| Revenue Growth | ★ 5.06 | N/A |
| 52 Week Low | $32.15 | $80.15 |
| 52 Week High | $53.47 | $109.36 |
Technical Indicators
Market Signals| Indicator | RPRX | FWONK |
|---|---|---|
| Relative Strength Index (RSI) | 68.50 | 51.41 |
| Support Level | $35.35 | $82.32 |
| Resistance Level | N/A | $91.44 |
| Average True Range (ATR) | 1.08 | 2.64 |
| MACD | 0.21 | 0.12 |
| Stochastic Oscillator | 81.19 | 46.17 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About FWONK Liberty Media Corporation Series C Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. It operates in two reportable segment Formula 1 and MotoGP. It generates majority of its revenue from the Formula 1 segment. The company derives its maximum revenue from United Kingdom.